Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9728043rdf:typepubmed:Citationlld:pubmed
pubmed-article:9728043lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9728043lifeskim:mentionsumls-concept:C1135918lld:lifeskim
pubmed-article:9728043lifeskim:mentionsumls-concept:C0458827lld:lifeskim
pubmed-article:9728043lifeskim:mentionsumls-concept:C0033554lld:lifeskim
pubmed-article:9728043lifeskim:mentionsumls-concept:C0086597lld:lifeskim
pubmed-article:9728043pubmed:issue3 Pt 1lld:pubmed
pubmed-article:9728043pubmed:dateCreated1998-10-5lld:pubmed
pubmed-article:9728043pubmed:abstractTextWe have previously reported that pretreatment of cultured human airway smooth muscle (HASM) cells with interleukin-1beta (IL-1beta) results in decreased beta-adrenergic responsiveness. The purpose of this study was to determine whether prostanoids released as a result of cyclooxygenase-2 (COX-2) induction by IL-1beta contribute to this effect of the cytokine. Confluent serum-deprived HASM cells were studied in passages 4-7. IL-1beta (20 ng/ml for 22 h) reduced the ability of the beta-agonist isoproterenol (Iso) to decrease stiffness of HASM cells as measured by magnetic twisting cytometry. The effect of IL-1beta on Iso-induced changes in cell stiffness was abolished by nonselective [indomethacin (Indo), 10(-6) M] and selective (NS-398, 10(-5) M) COX-2 inhibitors. Indo and NS-398 also inhibited both the increased basal cAMP and the decreases in Iso-stimulated cAMP production induced by IL-1beta. IL-1beta (20 ng/ml for 22 h) caused an increase in both basal (15-fold) and arachidonic acid (AA)-stimulated (10-fold) PGE2 release. Indo blocked basal and AA-stimulated PGE2 release in both control and IL-1beta-treated cells. NS-398 also markedly reduced basal and AA-stimulated PGE2 release in IL-1beta-treated cells but had no significant effect on AA-stimulated PGE2 release in control cells. Western blot analysis confirmed the induction of COX-2 by IL-1beta. Exogenously administered PGE2 (10(-7) M, 22 h) caused a significant reduction in the ability of Iso to decrease cell stiffness, mimicking the effects of IL-1beta. Cycloheximide (10 microg/ml for 24 h), an inhibitor of protein synthesis, also abolished the effects of IL-1beta on Iso-induced cell stiffness changes and cAMP formation. In summary, our results indicate that IL-1beta significantly increases prostanoid release by HASM cells as a result of increased COX-2 expression. The prostanoids appear to contribute to beta-adrenergic hyporesponsiveness, perhaps by heterologous desensitization of the beta2 receptor.lld:pubmed
pubmed-article:9728043pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:languageenglld:pubmed
pubmed-article:9728043pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:citationSubsetIMlld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9728043pubmed:statusMEDLINElld:pubmed
pubmed-article:9728043pubmed:monthSeplld:pubmed
pubmed-article:9728043pubmed:issn0002-9513lld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:MoellerWWlld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:HeyderJJlld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:ShoreS ASAlld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:PanettieriR...lld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:MooreP EPElld:pubmed
pubmed-article:9728043pubmed:authorpubmed-author:LaporteJ DJDlld:pubmed
pubmed-article:9728043pubmed:issnTypePrintlld:pubmed
pubmed-article:9728043pubmed:volume275lld:pubmed
pubmed-article:9728043pubmed:ownerNLMlld:pubmed
pubmed-article:9728043pubmed:authorsCompleteYlld:pubmed
pubmed-article:9728043pubmed:paginationL491-501lld:pubmed
pubmed-article:9728043pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:meshHeadingpubmed-meshheading:9728043-...lld:pubmed
pubmed-article:9728043pubmed:year1998lld:pubmed
pubmed-article:9728043pubmed:articleTitleProstanoids mediate IL-1beta-induced beta-adrenergic hyporesponsiveness in human airway smooth muscle cells.lld:pubmed
pubmed-article:9728043pubmed:affiliationPhysiology Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA.lld:pubmed
pubmed-article:9728043pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9728043pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:9728043pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9728043lld:pubmed